

WELCOME LETTER



Dear Colleagues and Friends,

It is with pleasure that I welcome you to Rome for the 6th International Meeting on New Drugs and New Insights in Breast Cancer, bringing together clinicians, mainly medical oncologists, and researchers including this year a substantial translational research component. The issues enlisted in this program, in particular including data from clinical trials stemming from that original basic research, demonstrate how the translation of basic research into practical clinical tools is particularly active in this disease.

The program has been designed in the pursuit of excellence and, as usually, all lectures will be presented by an international distinguished outstanding faculty who will report all their experiences and developments.

I look forward to joining you and I also hope you can enjoy a unique and pleasant stay in our wonderful City.

Francesco Cognetti

PROVIDER E.C.M. - ID 93

AIM Education

Via G. Ripamonti, 129 - 20141 Milan - Ph. +39 02 56601.1 - Fax +39 02 70048585
cme@aimgroup.eu - www.aimeducation.it

ORGANIZING SECRETARIAT

AIM Group International



Rome Office - Via Flaminia, 1068 - 00189 Rome - Ph. +39 06 33053.1 - Fax +39 06 33053249
breastcancer2019@aimgroup.eu - <http://web.aimgroupinternational.com/2019/breastcancer>

WITH AN UNRESTRICTED EDUCATIONAL GRANT OF

PRINCIPAL SPONSORS



MAJOR SPONSORS



SPONSORS



ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

6th International Meeting on New Drugs and New Insights in Breast Cancer

ROME, NOVEMBER 14-15, 2019

Regina Elena National Cancer Institute
Bastianelli Congress Centre

PRESIDENT: *Francesco Cognetti*

Under the patronage of



FACULTY



- | | |
|-------------------------------|--------------------------------------|
| G. Arpino, Naples (Italy) | W.J. Gradishar, Chicago (USA) |
| A. Awada, Brussels (Belgium) | V. Guarneri, Padua (Italy) |
| A. Bardia, Boston (USA) | D. Juric, Boston (USA) |
| E. Bria, Rome (Italy) | J. Lethiö, Stockholm (Sweden) |
| P. Bruzzi, Genoa (Italy) | C.L. Loprinzi, Rochester (USA) |
| E. Capobianco, Miami (USA) | V. Lorusso, Bari (Italy) |
| S. Cinieri, Brindisi (Italy) | P. Marchetti, Rome (Italy) |
| F. Cognetti, Rome (Italy) | C. Marchiò, Turin (Italy) |
| G. Curigliano, Milan (Italy) | R. Masetti, Rome (Italy) |
| C. De Angelis, Naples (Italy) | G. Mustacchi, Trieste (Italy) |
| A. De Censi, Genoa (Italy) | G. Naso, Rome (Italy) |
| S. De Placido, Naples (Italy) | C. Nistico', Rome (Italy) |
| L. Del Mastro, Genoa (Italy) | E. Perez, Rochester (USA) |
| M. Di Maio, Turin (Italy) | G. Piaggio, Rome (Italy) |
| M.J. Duffy, Dublin (Ireland) | L. Pusztai, New Haven (USA) |
| A. Fabi, Rome (Italy) | R. Salgado, Melbourne (Australia) |
| R. Falcioni, Rome (Italy) | M. Scaltriti, New York (USA) |
| G. Ferretti, Rome (Italy) | V. Serra Elizalde, Barcelona (Spain) |
| D. Generali, Cremona (Italy) | S. Tomao, Rome (Italy) |
| A. Gennari, Genoa (Italy) | A. Wells, Pittsburgh (USA) |
| L. Gerratana, Udine (Italy) | |
| P. Giacomini, Rome (Italy) | |

THURSDAY, NOVEMBER 14

09.00 Introduction (*F. Cognetti*)

1st SESSION

HER2 + TUMORS

Chairman: G. Mustacchi

09.20 Neoadjuvant and adjuvant treatment for early stage HER2-positive: in which new molecules do you hope? (*E. Perez*)

09.40 The intriguing combination of trastuzumab with new molecular target: the anti PI3k example (*W.J Gradishar*)

10.00 Tucatinib and antiHER2 molecules: update (*D. Generali*)

10.20 Discussion

10.30 Coffee break

LUMINAL TUMORS

Chairmen: A. Gennari, G. Piaggio

10.40 New targets (*M.J. Duffy*)

11.00 Resistance to CDK4/6 inhibitors: is there a light of hope? (*D. Juric*)

11.20 New therapeutic molecular approaches: PI3K inhibitors (*M. Scaltriti*)

11.40 Early phase studies with new SERDs and new molecular targets (*G. Curigliano*)

12.00 Discussion

12.10 Lecture

The gene signatures in early disease (*F. Cognetti*)

TRIPLE NEGATIVE TUMORS

Chairmen: A. Gennari, S. Tomao

12.30 Clinical management in the era of biomarkers and therapy (*E. Perez*)

12.50 New treatment insights (*A. Awada*)

13.10 Discussion

13.20 Lunch

2nd SESSION

EVOLUTION AND NEW INSIGHTS IN IMMUNOLOGY AND IMMUNOTHERAPY

Chairmen: S. De Placido, V. Lorusso

14.00 TILs: the next morphological biomarker for daily practice? (*C. Marchiò*)

14.20 Immunotherapy plus chemotherapy in early disease (*L. Gerratana*)

14.40 Can we identify the best biological companions of immunotherapy? (*L. Pusztai*)

15.00 Discussion

3rd SESSION

NEW CONCEPTS

Chairmen: E. Bria, G. Ferretti

15.10 Big data in oncology: value, limitations, challenges (*E. Capobianco*)

15.30 Biomarkers as end points: are we ready to write new studies? (*P. Bruzzi*)

15.50 The real world evidence in breast cancer: what has changed in the development of new drugs (*M. Di Maio*)

16.10 Discussion

Presenting: F. Cognetti

16.20 Lecture

Processing disease management can improve the disease outcome? (*R. Salgado*)

16.40 Discussion

FRIDAY, NOVEMBER 15

Presenting: P. Giacomini

09.00 Lecture

Liquid Biopsy in Breast Cancer: the State of the art (*J. Lehtiö*)

1st SESSION

PATHWAYS AND APPLICATION IN CLINICAL PRACTICE

Chairmen: G. Arpino, R. Falcioni

09.20 New drugs for old pathways (*A. Bardia*)

09.40 Old drugs for new pathways (*C. De Angelis*)

10.00 Discussion

2nd SESSION

CHEMOTHERAPY IN EARLY BC

Chairmen: L. Del Mastro, V. Guarneri

10.15 Lecture

Node positive and adjuvant chemotherapy: the debate continues (*L. Del Mastro*)

10.35 Parp-inhibitors: the “alter ego” of chemotherapy? (*V. Serra Elizaide*)

10.55 Discussion

11.10 Coffee break

3rd SESSION

PREVENTION AND LIFESTYLE

Chairmen: S. Cinieri, R. Masetti

11.20 Statins and the outgrowth of metastases (*A. Wells*)

11.40 The neverending story of Tamoxifen: old drugs, new tricks (*A. De Censi*)

12.00 Health dietary patterns and breast cancer (*P. Marchetti*)

12.20 Discussion

4th SESSION

NEW CONCEPTS IN SIDE EFFECTS MANAGEMENT

Chairmen: G. Naso, C. Nisticò

12.40 Non-Estrogenic Management of Menopausal Symptom (*C.L. Loprinzi*)

13.00 What women want: well-being in early disease (*A. Fabi*)

13.20 Discussion

13.45 Conclusions (*F. Cognetti*)

14.05 CME Text

14.05 Lunch

SCIENTIFIC COMMITTEE

P.F. Conte (Padua, I)

M. De Laurentis (Naples, I)

S. De Placido (Naples, I)

L. Del Mastro (Genoa, I)

S. Gori (Negrar-VR, I)

P. Pronzato (Genoa, I)

LOCAL SCIENTIFIC COORDINATORS

Alessandra Fabi

Michelangelo Russillo

LOCAL SCIENTIFIC COMMITTEE

Giovanna Catania

Simona Gasparro

Paola Malaguti

Paolo Marchetti

CONGRESS VENUE AND GENERAL INFORMATION

Meeting Venue

Regina Elena National Cancer Institute – Raffaele Bastianelli Congress Centre
Via Fermo Ognibene, 23 – 00144 Rome

Language

The official language of the Congress is English. Simultaneous translation will not be provided.

Certificate of attendance

Certificates are issued to all registered participants who will expressly make request at the Secretariat Desk at the end of the Congress.

ECM - Educazione Continua in Medicina - for Italian delegates only

L'evento è inserito nel Piano Formativo anno 2019 AIM Education – Provider nr. 93 ed è stato accreditato presso la Commissione Nazionale per la Formazione Continua con Obiettivo Formativo di Processo: integrazione interprofessionale e multiprofessionale, interistituzionale (8) per la Figura Professionale FARMACISTA con specializzazione nelle seguenti discipline FARMACIA OSPEDALIERA; FARMACIA TERRITORIALE; per la Figura Professionale BIOLOGO con specializzazione nella seguente disciplina BIOLOGO; per la Figura Professionale MEDICO CHIRURGO con specializzazione nelle seguenti discipline ONCOLOGIA; RADIOTERAPIA; CHIRURGIA GENERALE; CHIRURGIA PLASTICA E RICOSTRUTTIVA; ANATOMIA PATOLOGICA; RADIODIAGNOSTICA; MEDICINA GENERALE (MEDICI DI FAMIGLIA); per un numero massimo di n. 200 partecipanti.

Oltre tale numero e per professioni/discipline differenti da quelle accreditate non sarà possibile rilasciare i crediti formativi. Si precisa che i crediti verranno erogati a fronte di una partecipazione del 90% ai lavori scientifici e del superamento della prova di apprendimento con almeno il 75% delle risposte corrette.

L'EVENTO HA OTTENUTO NR. 8,4 CREDITI FORMATIVI – **ID ECM: 93-274679 - ED.1**

REGISTRATION INFORMATION

| | |
|--|-----------------------------|
| · Registration Fee | € 183,00 (VAT 22% included) |
| · Registration for doctors of Regina Elena National Cancer Institute | FREE |
| · Post graduate students | FREE |

The registration fee entitles delegates to the following:

- entry to scientific sessions
- 1 coffee break and 1 buffet lunch on November 14 and 15, 2019
- CME credits
- congress material
- certificate of attendance